Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

10x Genomics, Inc. - Common Stock (NQ:TXG)

61.54 -3.31 (-5.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 10x Genomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
3 Small-Cap Stocks with Open Questions
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
10x Genomics (TXG) Q2 2026 Earnings Call Transcript ↗
Atera demand drives spatial transition as booked orders exceed 2026 targets. 
Via The Motley Fool
Topics Earnings Intellectual Property World Trade
News headline image
5 Revealing Analyst Questions From 10x Genomics’s Q2 Earnings Call
10x Genomics’ second quarter results came in above Wall Street’s expectations for both revenue and profitability, yet the market responded negatively. Manage... 
Via StockStory
Topics Earnings
News headline image
1 High-Flying Stock to Own for Decades and 2 We Question
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo... 
Via StockStory
News headline image
10x Genomics Q2 Earnings Call Highlights ↗
10x Genomics (NASDAQ:TXG) reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara. Excluding non-recurring settlement... 
Via MarketBeat
Topics Earnings
News headline image
TXG Q2 Deep Dive: Atera Launch Signals Transition as Spatial Market Shifts
Biotech company 10x Genomics (NASDAQ:TXG) reported Q2 CY2026 results exceeding the market’s revenue expectations, but sales fell by 12.6% year on year to $15... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Unpopular Stock That Deserves Some Love and 2 That Underwhelm
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory
News headline image
10x Genomics’s (NASDAQ:TXG) Q2 CY2026: Strong Sales, Full-Year Outlook Slightly Exceeds Expectations
Biotech company 10x Genomics (NASDAQ:TXG) reported Q2 CY2026 results topping the market’s revenue expectations, but sales fell by 12.6% year on year to $151 ... 
Via StockStory
News headline image
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect
Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results this Thursday after market close. Here’s what to expect. 10x Genomics beat anal... 
Via StockStory
News headline image
1 Surging Stock with Solid Fundamentals and 2 Facing Headwinds
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos... 
Via StockStory
News headline image
1 Healthcare Stock to Keep an Eye On and 2 We Avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali... 
Via StockStory
News headline image
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HC... 
Via StockStory
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 Facing Challenges
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
3 Russell 2000 Stocks We Steer Clear Of
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ... 
Via StockStory
News headline image
3 Cash-Heavy Stocks We Find Risky
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c... 
Via StockStory
News headline image
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
1 Unprofitable Stock on Our Watchlist and 2 We Brush Off
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
Stocks making big moves this week: Qualcomm, Accenture, 10x Genomics, Seagate, and Lattice Semiconductor
Check out the companies making headlines this week: Qualcomm (NASDAQ:QCOM): Wireless chipmaker Qualcomm (NASDAQ:QCOM) fell by 4.7% on Wednesday after a lever... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
Why Is 10x Genomics (TXG) Stock Soaring Today
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 6.8% in the morning session after Barclays boosted its price target to $40 per shar... 
Via StockStory
News headline image
10x Genomics (TXG): Buy, Sell, or Hold Post Q1 Earnings?
The past six months have been a windfall for 10x Genomics’s shareholders. The company’s stock price has jumped 116%, setting a new 52-week high of $34.69 per... 
Via StockStory
Topics Supply Chain
News headline image
3 Small-Cap Stocks with Questionable Fundamentals
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors. ↗
10x Genomics, a leader in single cell and spatial genomics tools, reported a notable insider sale amid ongoing sector innovation. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The 5 Most Interesting Analyst Questions From 10x Genomics’s Q1 Earnings Call
10x Genomics' first quarter results were met with a negative market reaction, despite exceeding Wall Street’s revenue and earnings expectations. Management c... 
Via StockStory
Topics Artificial Intelligence Earnings
News headline image
United Natural Foods Stock Is Up 85%. One Investor Just Sold Out Completely ↗
United Natural Foods distributes natural, organic, and conventional groceries to a wide range of North American retailers. 
Via The Motley Fool
Topics Economy Supply Chain
News headline image
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year ↗
Supernus Pharmaceuticals delivers specialty therapies for CNS disorders, targeting healthcare providers and specialty pharmacies nationwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% ↗
10x Genomics provides advanced tools for single cell and spatial biology research, serving academic and biopharma institutions worldwide. 
Via The Motley Fool
News headline image
1 Cash-Producing Stock on Our Watchlist and 2 We Question
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
News headline image
10x Genomics Q1 Earnings Call Highlights ↗
10x Genomics (NASDAQ:TXG) reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the launch of Atera, a new spatial biology instrument... 
Via MarketBeat
Topics Earnings
News headline image
Why 10x Genomics (TXG) Stock Is Down Today
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.3% in the afternoon session after its first-quarter results, although beating expec... 
Via StockStory
News headline image
TXG Q1 Deep Dive: Atara Launch, Spatial Platform Transition, and AI-Driven Demand
Biotech company 10x Genomics (NASDAQ:TXG) announced better-than-expected revenue in Q1 CY2026, but sales fell by 2.6% year on year to $150.8 million. The com... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.